KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Debt to Equity (2016 - 2025)

Eli Lilly (LLY) has disclosed Debt to Equity for 17 consecutive years, with $1.6 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 32.05% year-over-year to $1.6, compared with a TTM value of $1.6 through Dec 2025, down 32.05%, and an annual FY2025 reading of $1.6, down 32.05% over the prior year.
  • Debt to Equity was $1.6 for Q4 2025 at Eli Lilly, down from $1.79 in the prior quarter.
  • Across five years, Debt to Equity topped out at $178.45 in Q4 2022 and bottomed at -$951.67 in Q3 2024.
  • Average Debt to Equity over 5 years is -$68.21, with a median of $1.77 recorded in 2022.
  • The sharpest move saw Debt to Equity surged 4690.01% in 2022, then plummeted 33885.58% in 2024.
  • Year by year, Debt to Equity stood at -$3.89 in 2021, then soared by 4690.01% to $178.45 in 2022, then crashed by 76.2% to $42.47 in 2023, then plummeted by 94.45% to $2.36 in 2024, then crashed by 32.05% to $1.6 in 2025.
  • Business Quant data shows Debt to Equity for LLY at $1.6 in Q4 2025, $1.79 in Q3 2025, and -$22.7 in Q2 2025.